REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
US FDA approves Rexulti as first drug for agitation in Alzheimer's
FDA OKs First Drug for Agitation in Alzheimer's Dementia
New Drug to Combat Common Problem in Alzheimer's Patients - Fisher
First FDA Approved Medication for Agitation Associated with
FDA Approves First Drug to Treat Alzheimer's Agitation
FDA panel backs approval of Rexulti for Alzheimer's-related agitation
FDA Approves Rexulti For Agitation Associated With Dementia Due To
Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation
Important News for Older Adults: FDA Approves First Drug to Treat
FDA approves first drug to treat agitation linked with Alzheimer's
Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation
Rexulti Works for Agitation in Alzheimer's, Despite Risks, Says
Otsuka and Lundbeck Issue Statement on FDA Advisory Committee
Insights & Implications in Gerontology: Agitation in Alzheimer's
Otsuka and Lundbeck Announce U.S. Food and Drug Administration
de
por adulto (o preço varia de acordo com o tamanho do grupo)
